Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Predominantly squamous cell histology * Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy * Advanced disease, meeting 1 of the following staging criteria: * Stage IIIB disease with malignant pleural effusion * Stage IV disease * Recurrent, unresectable disease * Measurable or nonmeasurable disease * No extrathoracic only disease * No known CNS metastases by head CT scan with contrast or MRI PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Platelet count \> 100,000/mm\^3 * Absolute neutrophil count \> 1,500/mm\^3 * Bilirubin \< 1.5 mg/dL * Transaminases \< 5 times upper limit of normal (ULN) * Creatinine clearance ≥ 45 mL/min * Urine protein:creatinine ratio ≤ 1.0 by spot urinalysis * INR \< 1.5 ULN * PTT normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients use effective contraception * No serious nonhealing wound, ulcer, or bone fracture * No ongoing or active infection * No ongoing fever * No myocardial infarction within the past 6 months * No stroke within the past 6 months * No history of hypertension unless well-controlled (i.e., blood pressure \< 150/100 mmHg on a stable regimen of antihypertensive therapy) * No New York Heart Association grade III or IV congestive heart failure * No serious cardiac arrhythmia requiring medication * No unstable angina pectoris * No peripheral vascular disease ≥ grade 2 * No other clinically significant cardiovascular disease * No abdominal fistula * No gastrointestinal perforation * No intra-abdominal abscess within the past 6 months * No psychiatric illness or social situation that would preclude study compliance * No other malignancy curatively treated within the past 5 years * No history of thrombotic or hemorrhagic disorders * No gross hemoptysis (i.e., red blood ≥ ½ teaspoon) within the past 3 months * No bleeding requiring intervention or ≥ grade 2 PRIOR CONCURRENT THERAPY: * Recovered from prior therapy * No prior systemic chemotherapy for metastatic NSCLC * More than 6 months since prior adjuvant chemotherapy for early stage (i.e., stage IB-IIIA) NSCLC * More than 3 weeks since prior immunotherapy, hormonal therapy, or radiotherapy * More than 28 days since prior and no concurrent major surgery * More than 7 days since prior minor surgery, fine-needle aspiration, or core biopsy * More than 4 weeks since prior and no concurrent participation in another experimental drug study * No concurrent therapeutic anticoagulation * Concurrent prophylactic anticoagulation of venous access device allowed * No concurrent chronic treatment with aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory drugs known to inhibit platelet function * No concurrent dipyridamole, ticlopidine, clopidogrel, or cilostazol